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Objectives: Our objectives were to (1) review our experience with heart
transplants in infants (age < 6 months), (2) delineate risk factors for
30-day mortality, and (3) compare outcomes between our early and recent
experience. Methods: Records of all infants listed for transplantation in our
center before September 1996 were analyzed. Early and recent comparisons
were made between chronologic halves of the accrual period. Univariate
analysis was used to analyze potential risk factors for 30-day mortality
(categorical variables, Fisher’s exact test; continuous variables, nonpara-
metric Wilcoxon rank-sum test). Multivariable analysis included univariate
variables with p values <2 0.10. Actuarial survivals were estimated (Kaplan-
Meier) and compared by the log-rank test. Results: Fifty-one of the 60
infants listed for transplantation were operated on (waiting list mortality
15%). Thirty-day mortality was 18% overall, 30% in the first 3 years and
10% in the last 3 years (p 5 0.07). Sepsis was the commonest cause of early
death (4/9). Univariate analysis suggested four potential risk factors for
early death: preoperative mechanical ventilation (p 5 0.01), prior sternot-
omy (p 5 0.002), preoperative inotropic drugs (p 5 0.08), and warm
ischemia time (p 5 0.08). Multivariable analysis indicated that prior
sternotomy (p 5 0.01) was an independent risk factor for 30-day mortality.
Actuarial survivals were 80%, 78%, and 70% at 1, 2, and 3 years, and these
figures improved between early and recent groups (p 5 0.05). Late deaths
were most commonly due to acute rejection (3/5). Conclusions: Results of
heart transplantation in infancy improve with experience. Prior sternotomy
increases initial risk. Intermediate-term survival for infants with end-stage
heart disease is excellent. (J Thorac Cardiovasc Surg 1998;116:242-52)
Orthotopic heart transplantation is the only avail-able treatment option for children with unrecon-
structible congenital heart defects and severe car-
diomyopathies. In addition, some centers now
prefer transplantation over the Norwood procedure
for infants with hypoplastic left heart syndrome and
for other congenital heart defects that require high-
risk single ventricle repairs. Intermediate results of
pediatric heart transplantation now approach the
results achieved in adult patients, with 2-year actu-
arial survivals of 70%.1 Because the number of
pediatric heart transplants performed by individual
institutions has been relatively small, the Pediatric
Heart Transplant Study (PHTS) conducted a multi-
institutional analysis to provide data on survival and
risk factors for perioperative mortality in children
aged 1 to 18 years.2 This group demonstrated that
younger age, requirement for pretransplantation
mechanical assistance, and nonidentical donor-re-
cipient ABO match were independent risk factors
for early mortality. Similarly, International Society
for Heart and Lung Transplant (ISHLT) data dem-
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onstrate decreased survival for children undergoing
transplantation under 1 year of age relative to older
children.1
Infants currently comprise the largest segment of
pediatric patients undergoing heart transplantation
in our center. ISHLT data indicate a similar world-
wide trend, with the total number of infant heart
transplantations performed numbering fewer than
100 per year.1 Unfortunately, the scarcity of donor
organs in this age group has limited the experience
of most pediatric heart transplant programs to fewer
than 35 infants.3-5 The only larger reported series is
from Loma Linda, California.6, 7 Consequently, few
single-center data are available regarding interme-
diate outcomes and perioperative risk factors for
infant heart transplantation.
Our cumulative experience with heart transplan-
tation in patients 18 years and younger now totals
112 transplants in 110 patients. We8 have previously
reported intermediate results in our patients older
than 6 months at the time of transplantation. The
purposes of this study are (1) to review our experi-
ence with heart transplantation performed in infants
listed at age less than 6 months, (2) to identify risk
factors for 30-day mortality in this age group, and
(3) to compare early and intermediate outcomes
between our early and more recent experience.
Methods
Patients and data collection. The records of all 60
infants aged 180 days or less who entered our heart
transplantation protocol between June 1990 and August
1996 were retrospectively reviewed. This accrual period
was selected so that all listed patients either underwent
transplantation or died awaiting transplantation. All in-
fants surviving to transplantation underwent operation
before January 1, 1997. No patients were lost to follow-up.
Autopsies were obtained in all cases of hospital and late
mortality.
Preoperative management. The primary diagnostic tool
in all cases was transthoracic two-dimensional echocardi-
ography. Cardiac catheterization was used selectively to
clarify anatomy not clearly delineated by echocardiogra-
phy and for preoperative palliative procedures. Pulmo-
nary vascular resistance was not specifically determined
because of the young age of this population. Pulmonary
artery banding was undertaken to protect the pulmonary
bed in patients with high-flow left-to-right shunts (e.g.,
unbalanced atrioventricular septal defects) when deemed
appropriate. The preoperative management of hypoplas-
tic left heart syndrome (HLHS) evolved considerably
during the course of this study. Patients with HLHS and
ductus-dependent systemic circulations were maintained
on intravenous alprostadil (prostaglandin E1). Initially,
strategies to reduce preoperative pulmonary vascular re-
sistance were used in the hope of avoiding donor right
heart failure after transplantation. More recently, we
followed strategies to increase pulmonary vascular resis-
tance to maintain hemodynamic stability while awaiting
transplantation.9 Inhaled nitrogen was administered to
limit pulmonary blood flow during the initial management
of patients with HLHS. Most patients were weaned from
nitrogen within 6 weeks. Atrial septal defects were left
restrictive unless excessive hypoxemia mandated balloon
atrial septostomy. Diuretics and inotropic support were
minimized. Mechanical ventilation was avoided whenever
possible. Patients with HLHS variants (i.e., Shone’s syn-
drome) anticipated to have adequate antegrade aortic
arch flow to support systemic circulatory requirements
long enough to allow transplantation underwent ductal
division and coarctation repair.
Perioperative management. Perioperative pulmonary
artery pressures and mixed venous oxygen saturations
were continuously measured in all patients with oximetric
pulmonary artery catheters (Abbott Laboratories, Inc.,
Chicago, Ill.). Donor hearts were procured in standard
fashion including extra great vessel lengths as dictated by
recipient anatomy. Roe’s solution was used for donor
cardioplegia. Whenever possible, total ischemia time was
limited to less than 4 hours. The majority of cases were
performed by a cardiothoracic surgery resident assisted by
an attending cardiothoracic surgeon. Circulatory arrest
was used during the entire implantation procedure for all
ductus-dependent patients with HLHS and when required
by patient anatomy or small size. Circulatory arrest fol-
lowed by low-flow bypass was not used. Isoproterenol and
dopamine were routinely used for inotropic support.
Dobutamine and epinephrine were used when additional
inotropic support was required. Beginning in October
1993, inhaled nitric oxide and intravenous milrinone infu-
sions were routinely used when elevated pulmonary vas-
cular resistance was anticipated or encountered. Periop-
erative immunosuppression consisted of cyclosporine
(INN: ciclosporin), azathioprine, and methylprednisolone.
Induction therapy with antithymocyte serum (American
Medical Resources, Nashville, Tenn.) was used with rapid
discontinuation of methylprednisolone. Serial echocardio-
grams were used extensively to detect early rejection
according to established criteria.10
Long-term management. After hospital discharge, in-
fants were serially examined and echocardiograms per-
formed frequently. Corticosteroids were not used for
long-term immunosuppression. Cyclosporine and azathio-
prine were given for the first 18 months. More recently,
mycophenolate mofetil was used in lieu of azathioprine.
Endomyocardial biopsy was used only rarely in the assess-
ment of acute rejection. Routine catheterizations with
endomyocardial biopsies and coronary angiograms (re-
cently including intravascular ultrasound) were performed
18 and 36 months after transplantation to detect chronic
rejection and cardiac allograft vasculopathy. In the ab-
sence of chronic rejection and cardiac allograft vasculopa-
thy, azathioprine was discontinued after 18 months, and
cyclosporine monotherapy was used thereafter. Func-
tional development was subjectively assessed by nurse
coordinators and transplant cardiologists at each fol-
low-up visit. For purposes of outcome analysis, functional
development was determined by review of most current
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follow-up documentation and categorized as good or
developmentally delayed.
Definitions. Waiting list time for patients listed in utero
was calculated from the date of birth. Pretransplantation
procedures were defined as any operative or catheter-
based intervention attempted to correct or palliate a
congenital cardiac defect. Total ischemia time was defined
as the time between donor aortic clamping and reperfu-
sion of the donor heart. Warm ischemia time was consid-
ered to equal the circulatory arrest time or recipient total
aortic clamp time when standard bypass techniques were
used. The heterogeneous group of congenital heart dis-
eases in this series cannot allow meaningful risk analysis
by individual lesion; therefore diagnoses were categorized
as HLHS or non-HLHS. July 15, 1993, was the chrono-
logic midpoint of this series and was chosen as the dividing
point between our early and recent experience. Respira-
tory failure was defined as postoperative mechanical
ventilation exceeding 10 days. Delayed posttransplanta-
tion interventions were defined as any operative or cath-
eter-based intervention (excluding routine biopsies and
angiography) required as a direct consequence of trans-
plantation and occurring more than 30 days after trans-
plantation.
Data analysis and statistical methods. Patient height
and weight at the time of transplantation and at most
recent follow-up were compared with National Center for
Health Statistics growth curves.11 Potential predictors of
30-day mortality included diagnosis, recipient weight,
donor/recipient weight ratio, age at transplantation, time
awaiting transplantation, preoperative dependence on
mechanical ventilation, preoperative dependence on ino-
tropic agents, total ischemia time, warm ischemia time,
prior sternotomy, recipient blood type, and nonidentical
ABO match. These predictors were evaluated by univar-
iate analysis by means of Fisher’s exact test for categorical
variables and nonparametric Wilcoxon rank-sum test for
continuous variables. Multivariable analysis was per-
formed with logistic regression including all variables with
p values # 0.10 by univariate analysis. Age at listing, age
at transplantation, recipient weight, donor/recipient
weight ratio, diagnosis, waiting time to transplantation,
total ischemia time, warm ischemia time, hospital stay,
intensive care stay, time of mechanical ventilation, time of
inotropic support, and 30-day mortality were compared
between early and recent groups by means of Fisher’s
exact test for categorical variables and the nonparametric
Wilcoxon rank-sum test for continuous variables. Survival
curves were estimated with the use of the Kaplan-Meier
method and survival curves were compared between the
early and recent series by means of the log-rank test. The
Cox proportional hazards model was used to model
survival for the early and recent series with transplanta-
tion as a time-dependent covariate. Patients listed but not
undergoing transplantation were included in the latter
analysis. Patients electively removed from the waiting list
were excluded. All statistical analyses were performed
with the SAS System version 6.12 (SAS, Inc., Cary,
N.C.).12
Results
Pretransplantation course. Fifty-one of 60 in-
fants entered into our transplant protocol during
this study underwent orthotopic heart transplanta-
tion. The diagnoses of all patients undergoing trans-
plantation are listed in Table I. All nine patients not
undergoing transplantation died. Six with HLHS
and one patient with a restrictive cardiomyopathy
died while on the waiting list, and two infants (1
Table I. Diagnoses of 51 infants undergoing
transplantation
Diagnosis No.
HLHS (ductus-dependent) 25
Shone’s syndrome 8
Pulmonary atresia, intact ventricular septum, sinu-
soids
4
Unbalanced AVSD 3
Hypertrophic cardiomyopathy 2
Tricuspid atresia, TGA, hypoplastic RV, coarcta-
tion
2
Tricuspid atresia, TGA, IAA, hypoplastic RV 1
Tricuspid atresia, sinusoids, EFE, complete heart
block
1
Truncus arteriosis, TS, TI, hypoplastic LV 1
Truncus arteriosis, TS, truncus arising from RV 1
SV, single atrium, AVSD, left SVC, bilateral IVC,
polysplenia
1
SV, pulmonary atresia, TAPVR, asplenia 1
Spongy myocardium 1
AVSD, Atrioventricular septal defect; EFE, endocardial fibroelastosis;
HLHS, hypoplastic left heart syndrome; IAA, interrupted aortic arch; IVC,
inferior vena cava; LV, left ventricle; RV, right ventricle; SV, single
ventricle; SVC, superior vena cava; TAPVR, total anomalous pulmonary
venous return; TGA, transposition of great arteries; TI, truncal valve
insufficiency; TS, truncal valve stenosis.
Table II. Major pretransplantation interventions
Procedures No.
Balloon atrial septostomy 19 (15)
Coarctation repair and PA band 6
Modified Blalock-Taussig shunt 5
PA band 4
Balloon aortic valvuloplasty 4 (3)
Coarctation repair 3
Diaphragm plication 2
Central aortopulmonary shunt 1
Aortopulmonary shunt band and pacemaker 1
Mitral valve replacement 1
Common AV valve repair and PA band 1
Interrupted arch repair and PA band 1
Open atrial septostomy 1
Balloon truncal valvuloplasty 1
Balloon pulmonary valvuloplasty 1
Total 51 (32)
Numbers in parentheses indicate number of affected patients. AV, Atrio-
ventricular; PA, pulmonary artery.
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HLHS, 1 failed repair of D-transposition of the
great arteries and multiple ventricular septal de-
fects) were removed from the waiting list and later
died. Overall waiting list mortality was 15%. Ex-
cluding the two patients who were removed from
the list, waiting list mortality was 12%. There were
no deaths while awaiting transplantation during
the last 22 months of patient accrual. Mean age at
listing was 39 6 46 days (range, birth to 160 days),
and mean wait time for transplantation was 69 6
47 days. While awaiting transplantation, 32 pa-
tients required 51 major interventions (Table II).
Nineteen balloon atrial septostomies were per-
formed in 15 patients. Six pretransplantation pro-
cedures in five patients necessitated median ster-
notomies.
Operative course. Thirty-nine boys and 12 girls
underwent transplantation at a mean age of 107 6
66 days. ABO blood groupings of the recipients
were 27 type O, 18 type A, and 6 type B. Eight
recipients received nonidentical blood group donor
hearts. Deep hypothermia with circulatory arrest
was used in 33 patients with a mean circulatory
arrest time of 66.2 6 12.5 minutes. Standard cardio-
pulmonary bypass was used in the other 18 infants.
Perioperative variables and initial courses of the
patients are summarized in Table III.
Perioperative course. Thirty-day mortality in this
study was 18% (9/51; 95% confidence limits: 7% to
28%). Diagnosis leading to transplantation, cause of
death, and time to death of the nine patients who
died in the perioperative period are presented in
Table IV. Four of nine early deaths were due to
sepsis. Renal failure necessitating peritoneal dialysis
occurred in all four patients who died of sepsis and
in one patient who died 8 days after resuscitation
from a pulmonary hypertensive crisis necessitating
extracorporeal membrane oxygenation (ECMO).
Univariate analysis identified four variables po-
tentially predictive of 30-day mortality: preoperative
dependence on mechanical ventilation (p 5 0.01),
prior sternotomy (p 5 0.002), preoperative depen-
dence on inotropic agents (p 5 0.08), and warm
ischemia time (p 5 0.08). No other variables were
associated with 30-day mortality. By multivariable
analysis, only prior sternotomy (p 5 0.01) was
Table III. Operative variables and outcomes for the entire series
Variable Mean 6 SD Median Range
Age at listing (days) 38.7 6 45.6 15 0-160
Age at transplantation (days) 107.4 6 66.4 95 10-315
Wait to transplantation (days) 68.6 6 47.1 65 7-297
Weight at transplantation (kg) 4.8 6 1.1 4.6 2.5-7.8
Donor/recipient weight ratio 1.79 6 0.63 1.75 0.79-3.33
Total ischemia (min) 233.9 6 75.1 240 69-526
Warm ischemia (min) 61.4 6 13.0 61 37-99
Hospital stay (days) 26.3 6 67.6 10 1-439
Intensive care stay (days) 23.5 6 65.6 7 0-419
Ventilator support (days) 16.0 6 58.7 4 0-419
Inotropic support (days) 6.3 6 4.8 5 0-28
Table IV. Causes of 30-day mortality
Patient Diagnosis Cause of death Postop. day
2 HLHS Enterobacter sepsis 20
6 Unbalanced AVSD Candida sepsis 7
9 Hypertrophic cardiomyopathy Sudden death 1
11 HLHS Pulmonary hypertensive crisis 3
15 SV, PA, TAPVR, asplenia Technical Intraoperative
20 Shone’s syndrome Pseudomonas sepsis 20
32 Truncus arteriosis, TS Technical Intraoperative
36 HLHS Pulmonary hypertensive crisis 8
49 SV, polysplenia Pseudomonas sepsis 3
AVSD, Atrioventricular septal defect; HLHS, hypoplastic left heart syndrome; PA, pulmonary artery; SV, single ventricle; TAPVR, total anomalous pulmonary
venous return; TS, truncal valve stenosis.
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independently predictive of 30-day mortality. Table
V summarizes the results of the risk factor analysis.
The median hospital and intensive care stays after
transplantation for the entire series were 10 and 7
days (Table III). Median durations of mechanical
ventilator support and inotropic support were 4 and
5 days, respectively. Inhaled nitric oxide became
available to us in October 1993 and was used in 22 of
31 patients undergoing transplantation after that
time, for an average duration of 4.2 days (range 1 to
18 days). ECMO was used in five patients (3 HLHS,
1 Shone’s syndrome, 1 single ventricle with polysple-
nia), of whom three were successfully weaned and
remain alive. Hemiparesis developed in one ECMO
survivor as a result of intracerebral hemorrhage. All
three survivors (2 HLHS, 1 Shone’s syndrome) had
right heart failure as a result of excessive pulmonary
vascular resistance and were supported for an aver-
age of 3.0 days. Both deaths on ECMO were due to
sepsis. One patient with HLHS was placed on
ECMO 9 hours after the operation after a pulmo-
nary hypertensive crisis and died of fulminant sepsis
after 8 days of support. Another infant placed on
ECMO 3 days after the operation was supported
only 4 hours and at autopsy was found to have had
hemodynamic collapse from overwhelming Pseudo-
monas sepsis.
Table VI details perioperative comparisons be-
tween the early and recent series. The percentages
of patients with and without HLHS were nearly
identical between series (early group, 45% HLHS;
recent group, 52% HLHS). The only variable differ-
ent between groups was a smaller donor/recipient
weight ratio in the early group (1.4 6 0.5 vs 2.0 6
0.6, p 5 0.003). Given the larger number of 30-day
deaths in the early group and smaller number of
patients in this group, differences in hospital and
intensive care stays are masked by the relatively
shorter outcomes of these patients; however, this
effect is countered by 2 outliers in the early group
with hospital stays of 439 and 235 days. Excluding all
30-day deaths from both the early and recent series
and the 2 outliers in the early group as mentioned
above, hospital stay for the recent series was shorter
than in the early experience (mean 20.8 vs 12.8 days,
p 5 0.03). Similarly, intensive care stay also declined
(mean 17.8 vs 9.6 days, p 5 0.04). Although not
statistically significant, the 30-day mortality differ-
ence of 30% versus 10% (p 5 0.07) suggests im-
proved early outcome in the recent series.
Perioperative complications. Fifty-two complica-
tions occurred in 23 of the 42 operative survivors
and are listed in Table VII. Eight cardiac arrests
were successfully resuscitated in six patients. Three
patients’ chests were reopened on an emergency
basis, and one of these patients was placed on
ECMO. The remaining arrests responded to exter-
nal compressions and pharmacologic resuscitation.
Delayed sternal closure was required in seven pa-
tients: three after decannulation from ECMO, two
after emergency open chest resuscitations, and two
patients’ chests were intentionally stented open in
the postoperative period to allow for resolution of
myocardial edema. There were no wound complica-
tions in these patients. Two patients underwent
exploration for postoperative mediastinal hemor-
rhage, one of whom was supported by ECMO.
Long-term results. Mean follow-up length for the
series was 27.9 6 21.4 months. Excluding all early
deaths, mean follow-up was 33.8 6 18.8 months
(range 7.4 to 81.5 months). Forty-one of the 42
30-day survivors were discharged from the hospital
alive. Five late deaths occurred at an average post-
transplantation survival of 19.3 6 8.8 months. One
Table V. Risk factors for 30-day mortality
Risk factor
Univariate Multivariable
p Value Odds ratio 95% confidence interval p Value
Age at listing (days) 0.69
Age at transplant (days) 0.78
Wait to transplant (days) 0.85
Weight at transplant (kg) 0.44
Donor/recipient weight ratio 0.37
Nonidentical ABO match 0.18
Total ischemia (min) 0.68
Warm ischemia (min) 0.08 1.07 0.99-1.16 0.10
Preoperative mechanical ventilation 0.01 4.26 0.34-53.8 0.26
Preoperative inotropic support 0.08 0.84 0.99-1.16 0.21
Prior sternotomy 0.002 60.1 2.25-999 0.01
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late death occurred in a patient who remained
hospitalized 235 days. This patient had multiple
complications, required nine major posttransplanta-
tion interventions, and ultimately died of over-
whelming sepsis. Acute rejection was the most com-
mon cause of late death, accounting for three
deaths. The other late death was caused by post-
transplantation lymphoproliferative disease with
central nervous system involvement. The latter pa-
tient accounted for the only case of posttransplan-
tation lymphoproliferative disease in the entire se-
ries. Only one patient in the series had a second
transplantation. Actuarial survival of the entire se-
ries is depicted in Fig. 1. One-, 2-, and 3-year
survivals were 80%, 78%, and 70%, respectively.
Mean lengths of follow-up for the early and late
groups were 35.2 6 29.6 months and 23.1 6 12.2
months, respectively. Fig. 2 depicts actuarial survival
of the early and recent groups. Actuarial survival
was improved in the recent group (p 5 0.05), with a
Table VI. Early versus recent series comparisons
Variable
Early group (n 5 20) Recent group (n 5 31)
p
ValueMinimum
10th
percentile Median
90th
percentile Maximum Minimum
10th
percentile Median
90th
percentile Maximum
Age at listing
(days)
3 4.5 11.5 118.5 138 0 9 18 88 160 0.27
Age at transplan-
tation (days)
16 40 93 174 207 10 42 96 246 315 0.49
Wait to trans-
plantation
(days)
7 31.5 51.5 91.5 95 7 30 70 138 297 0.30
Weight at trans-
plantation (kg)
2.5 3.4 4.3 6.2 7.8 3.4 3.8 4.6 6.1 7.2 0.43
Donor/recipient
weight ratio
0.8 0.9 1.3 2.1 2.3 1.0 1.2 2.1 2.7 3.3 0.003
Total ischemia
(min)
90 135 220 270 285 69 132 253 329 526 0.07
Warm ischemia
(min)
37 43.5 62 84.5 99 43 46 60 71 84 0.39
Hospital stay
(days)
1 2.5 11.5 145.5 439 1 7 9 20 47 0.07
Intensive care
stay (days)
0 2.5 11.5 145.5 419 0 4 7 13 43 0.06
Hospital stay
(days)*
9 10 11.5 40 56 5 7 10 20 47 0.03
Intensive care
stay (days)*
3 5 11.5 40 56 3 4 7 17 43 0.04
Inotropic support
(days)
0 1.5 5 15 18 0 3 5 9 28 0.84
Ventilator sup-
port (days)
0 2 4 50 419 0 2 4 10 38 0.70
Asterisks (*) indicate comparisons after censoring 2 outliers from the early group and all 30-day mortalities from each group (see text). Diagnoses were similar
between groups (early 9/20 HLHS, recent 16/31 HLHS).
Table VII. Perioperative complications in 30-day
survivors
Complication No.
Cardiac arrest 8 (6)
Acute rejection 8 (6)
Delayed sternal closure required 7
Respiratory failure 7
Septicemia 4
Renal failure requiring peritoneal dialysis 3
Graft failure requiring ECMO 3
Cytomegalovirus infection 2
Bleeding requiring reoperation 2
Small bowel obstruction 2 (1)
SVC obstruction/chylothorax 1
Chylothorax 1
Hemothorax 1
Pneumothorax 1
Intracerebral hemorrhage 1
Calcium chloride extravasation 1
Total 52 (23)
Numbers in parentheses indicate number of affected patients. ECMO,
Extracorporeal membrane oxygenation; SVC, superior vena cava.
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2-year survival of 86%. With the use of the Cox
proportional hazards model with transplantation
analyzed as a time-dependent covariate, survival was
also better in the recent group (p 5 0.04, risk ratio
0.39), and transplantation did not affect the differ-
ence between groups (p 5 0.99).
Eighteen operative survivors have had no acute
rejections at an average time at risk of 31.9 6 18.5
months. Of nine patients surviving less than 30 days,
only one had acute rejection. The number of acute
rejections in the remaining long-term survivors
ranged from one to six episodes per patient. Cardiac
allograft vasculopathy developed in two patients.
One patient required a second transplant operation
67.7 months after the initial transplantation because
of severe cardiac allograft vasculopathy. Cardiac
allograft vasculopathy was identified at postmortem
examination in a second patient who died of acute
rejection 30.4 months after transplantation. The
requirement for major interventions after transplan-
tation was substantial. Excluding all interventions
undertaken within the first 30 posttransplantation
days, 18 major interventions were required in 10
patients (Table VIII).
At the time of transplantation the mean height
and weight for the entire series corresponded to the
7th and 5th percentiles based on standard growth
curves. At most recent follow-up, mean standard-
ized heights and weights of operative survivors were
in the 20th and 16th percentiles, respectively.
Fig. 1. Kaplan-Meier survival curve of 51 infants having transplantation over a 6-year period. Tick marks
indicate censored observations. Error bars denote one standard error.
Fig. 2. Kaplan-Meier survival curves of 20 patients (early series) listed for heart transplantation before
July 15, 1993, and 31 patients (recent series) listed thereafter (p 5 0.05). Tick marks indicate censored
observations. Error bars denote one standard error.
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Among 37 remaining survivors, current functional
performance was good in 34 and developmentally
delayed in 3.
Discussion
Heart transplantation has become an established
therapy in children with heart disease not amenable
to other options. In addition, transplantation has
been used for HLHS in several centers.3, 7 Conse-
quently, the number of pediatric transplants per-
formed increased rapidly after the introduction of
this therapy. As previously observed in adults, the
number of pediatric heart transplants has now pla-
teaued. Approximately 100 procedures in the infant
age group per year were reported to the ISHLT in
1994 and 1995.1 Considering that 1500 to 2000
infants per year are born in North America with
HLHS, not to mention other causes of end-stage
heart disease, the number of potential candidates
who could benefit from transplantation far exceeds
the supply of donors. Unfortunately, little informa-
tion exists to guide appropriate allocation of scarce
infant donor organs.
Previous reported single-center experiences with
infant heart transplantation have not demonstrated
perioperative risk factors for mortality, most likely
because of relatively small sample sizes.3-5 The
Loma Linda series, despite 153 patients, also did not
delineate any preoperative risk factors predictive of
mortality.6 One report by Turrentine and col-
leagues13 suggested that a donor/recipient weight
ratio greater than 2.5 adversely affected survival.
However, a much larger study specifically examining
donor/recipient weight ratio found that size mis-
matching did not influence perioperative mortali-
ty.14 Within the range of our data, we did not
observe an influence of donor/recipient weight ratio
on 30-day mortality. By multivariable analysis the
Loma Linda series suggested an association between
graft total ischemia time greater than 240 minutes
and operative mortality (p 5 0.07). We did not
observe this association; however, the median isch-
emia time of our series was 240 minutes compared
with 270 minutes in the Loma Linda series. In
addition, the power of their series was much greater,
with a threefold larger sample size.
Our results indicate that prior sternotomy in-
creases the risk of 30-day mortality after heart
transplantation in infancy. However, the wide 95%
confidence intervals for this variable (Table V) and
the small size of our study introduces inherent
uncertainty, and this result must be interpreted with
this provision in mind. Interestingly, prior sternot-
omy was predictive of operative mortality in a recent
multiinstitutional analysis of 141 infants (age , 1
year) who underwent heart transplants.15 This re-
port from the PHTS identified three other indepen-
dent predictors of operative mortality in this age
group: nonidentical blood type donor, recipient
non-blood group A, and donor cause of death other
than head trauma. Unfortunately, our data were too
incomplete to allow analysis of donor cause of death
as a risk factor, and we did not observe an associa-
tion between nonidentical donor-recipient blood
type or any blood group with 30-day mortality. The
small sample size of our data, however, clearly limits
the power of our series to delineate these factors.
The PHTS report found no association between
total graft ischemia and early mortality; however,
warm ischemia time was not assessed.15 In addition,
no other single-center reports have examined this
variable. Although the p value is only at the 90%
confidence level, we observed a possible association
between warm ischemia and 30-day mortality that
we believe is clinically relevant. The reported warm
ischemia times in our data (range 37 to 99 minutes)
were considered to equal the crossclamp and circu-
latory arrest times recorded by the perfusionists
during each case. Consequently, these times overes-
timate the true warm ischemia times because our
practice is to keep the donor heart on ice until the
native heart is excised. From our logistic model the
odds ratio for early death at any duration of warm
ischemia x (within the range 37 to 99 minutes) is
given by the formula EXP(b[x – 37]), where b 5
0.675 (i.e., the parameter estimate for this variable).
Thus the duration of warm ischemia had an expo-
Table VIII. Major delayed posttransplantation
interventions
Procedure No.
Recoarctation balloon angioplasty 5
Balloon angioplasty for ascending aorta stricture 2
SVC balloon angioplasty 2 (1)
Tracheostomy 2
Thoracic duct ligation 1
Thoracic duct ligation/direct atrial venous access 1
Thoracotomy for venous access removal 1
Repair diaphragmatic hernia 1
Decortication 1
Lower extremity amputation 1
Retransplantation 1
Total 18 (10)
Numbers in parentheses indicate number of affected patients; SVC,
superior vena cava.
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nential effect on the risk of 30-day mortality. The
uncertainty in our data owing to small sample size
and the p value of only 0.10 implies that this function
should not be directly applied by other investigators,
although it is logical to expect a marked increase in
the risk of early mortality at extended warm isch-
emia times. Clinically, efforts to minimize warm
ischemia should improve outcomes.
Overall 1-month survival in the current series was
82% (95% confidence limits: 72% to 93%), which is
comparable with most other series.3-7, 13, 15 Causes
of early death were similar to those reported previ-
ously in this age group. As noted by Chinnock and
colleagues,6 heart transplantation in infants carries a
significant learning curve. The clinical characteris-
tics of our early and more recent series were nearly
indistinguishable (Table VI). Although not statisti-
cally significant, 1-month survival appears to have
improved to 90% (95% confidence limits: 74% to
96%) over the last 3 years of this study compared
with 70% (95% confidence limits: 49% to 86%) in
the first 3 years. Hospital and intensive care unit
stays decreased significantly. Renal failure was less
common in the latter half of our series, as only one
patient in the recent half required peritoneal dialysis
compared with five in the early half. In addition to
increased experience, we believe that other ad-
vances have improved our results. The perioperative
management of pulmonary vascular resistance has
improved with the use of milrinone and the recent
addition of nitric oxide, and the aggressive use of
ECMO has also allowed salvage of three patients
who would otherwise have died of excessive pulmo-
nary vascular resistance. Second, in addition to
improving pretransplantation survival in patients
with HLHS, our strategy to maintain systemic per-
fusion has improved the hemodynamic stability of
these patients, allowing us to avoid the use of
mechanical ventilation and inotropic support before
transplantation.9 Recently, we have discharged sev-
eral infants with HLHS to home while awaiting
transplantation. Other authors have noted that the
perioperative management of infants with HLHS is
particularly challenging.3, 4, 13 The HLHS early mor-
tality in our experience (12%) is similar to that of
other series.
Long-term survival in this series is comparable
with that of other reports and supports the efficacy
of transplantation in this age group, with 2-year
survivals of 78% overall and 86% more recently.
ISHLT data indicate an overall 2-year survival of
62% for children younger than 1 year of age at
transplantation.1 Similarly, the PHTS reported a
2-year survival of 69%.14 The improvement in long-
term outcome we found with increased experience
was most heavily influenced by the lower early
mortality (Fig. 2). Posttransplantation malignant
disease and cardiac graft vasculopathy were rare in
our experience. With longer follow-up the incidence
of these complications may increase.6, 16 We believe
that these results support our immunosuppression
regimen. In particular, avoidance of corticosteroids
for long-term immunosuppression appears advanta-
geous in infants and young children. In our experi-
ence, growth is satisfactory with progression to
higher growth curves during follow-up. In contrast,
one center that used long-term triple drug immuno-
suppression reported that infants undergoing trans-
plantation tended to remain at the same percentile
on the growth curve.3 Development of these infants,
although only subjectively assessed, appears quite
good and compares favorably with that of other
children who have undergone major corrective pro-
cedures for congenital heart disease during infancy.
In conclusion, our results further support the role
of heart transplantation in infants with end-stage
heart disease. The large number of pretransplanta-
tion and delayed posttransplantation interventions
and the substantial incidence of perioperative com-
plications indicate that infant transplantation is an
extremely labor-intense endeavor. Furthermore,
substantial resources must be invested in the long-
term follow-up of these patients, and the learning
curve associated with developing a program for
infant heart transplantation is significant. Unfortu-
nately, the scarcity of infant donor hearts is likely to
contribute to continued mortality while awaiting
transplantation. Advances that improve pretrans-
plantation survival are gratifying but may serve to
further increase demand on a limited donor supply.
Alternative solutions including xenograft transplan-
tation and mechanical heart systems deserve further
research.
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Discussion
Dr. Steven R. Gundry (Loma Linda, Calif.). I take
particular delight in noting that two of the authors on this
paper have been affiliated with our staff at Loma Linda.
Mark Boucek, MD, was a faculty member at Loma Linda
and David Fullerton, MD, was a fellow on our staff. David
Fullerton, who is now a member of the WTSA, won the
Samson Prize for a paper on infant heart transplantation
while he was at Loma Linda. It is a pleasure to discuss this
paper.
The authors have demonstrated, as have several others
in the past, that there is a significant learning curve in
infant heart transplantation and it is only when a center
commits a large resource in terms of time and people to
acquiring this learning curve that the results so dramati-
cally increase. Perhaps most important is the fact that the
authors have adopted a hands-off approach to the man-
agement of infants in the preoperative period. Perhaps
you would like to comment on that. What have you found
that has allowed these infants to survive for 3 or 4 months
while awaiting transplantation?
Dr. Mitchell. Our hats have to go off to our cardiolo-
gists for really flying in the face of conventional manage-
ment of these children, particularly those with HLHS.
Obviously, all of these children have to be managed with
prostaglandins to keep their ducts open to provide sys-
temic perfusion. We have tried to minimize pulmonary
flow and preserve systemic perfusion. To accomplish this,
we have administered inhaled nitrogen to the children
during the early days of life, and usually within 6 weeks
they can be weaned from nitrogen. The objective is to try
to preserve distal organ function and systemic flow by
reducing flow into the lungs, thereby reducing the need
for mechanical ventilation and reducing the need for
preoperative inotropic support. This strategy has actually
worked far better than we anticipated. In fact, in the past
6 months three children with HLHS have actually been
sent home with long-term infusions of prostaglandins
while awaiting transplantation. We try not to use a lot of
diuretics. In fact, we have found that the children can
maintain their own fluid balance if they are allowed to eat
what they want and if we try not to manipulate their
system other than to keep their ducts open and to limit
pulmonary blood flow.
Dr. Gundry. We had the same experience. Our neona-
tologists pioneered this, that is, the less they did, the less
mechanical ventilation, the less intravenous solutions in
these children, the better the children fared. Second, you
noted that your warm ischemia time correlated with a
decreased survival. Recently, we have changed our tech-
nique, particularly in the children with HLHS, to continue
to perfuse the body through the cannula, through the
snared ductus, while excising the heart and using sucker
bypass to reimplant the right atrial and left atrial
anastomoses. Only at that time do we institute circula-
tory arrest to reconstruct the arch. This has allowed us
to cut our circulatory arrest time to approximately 15
minutes in the last 50 children whom we have treated.
Do you think that the warm ischemia time with lessened
survival implies that more complex reconstructions
were needed in these groups, or does it imply that
perhaps you had trouble in these patients? You said
that two of your deaths were the result of technical
errors in complex reconstructions.
Dr. Mitchell. I think the answer to that is yes and no; for
example, if you look only at the group of children with
HLHS, the total ischemia times averaged 66 minutes,
which was above the mean average for the entire group.
However, their mortality was the lowest of the three
groups. On the other hand, in the children with more
complicated defects, there is certainly a longer require-
ment for ischemia to insert those grafts in. You referred to
the two technical problems: One was a child with anom-
alous pulmonary venous return in whom we could not
adequately identify all of the pulmonary venous return,
and we never weaned that child off the pump. The second
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was a child who had very small pulmonary arteries, which
we did not realize in the preoperative workup, again
setting us up for acute right heart failure. More compli-
cated cases are going to be associated with longer isch-
emia times. Certainly there are some confounding influ-
ences between time and the particular diagnosis.
Dr. Gundry. Last is your fairly new use of nitric oxide
and milrinone in the postoperative management of these
children. This is intriguing to me because we have not
seen any evidence of pulmonary hypertension, particularly
in the children with HLHS, even undergoing transplanta-
tion at age 5 or 6 months. Do you think that pulmonary
hypertension in your patient population is related to the
high altitude at which these children are kept and your
operations are performed?
Dr. Mitchell. We think that may be a factor. The
problem becomes more severe the longer the children
have to wait. However, since we do not have enough
numbers to show that statistically, I did not even try.
Just anecdotally, several children have waited 5 months
and one 6 months. Two of three at that duration have
survived, but it has been much more difficult, and some
of those children have required ECMO to get through the
operation.
Commentary
This series of infants undergoing heart transplanta-
tion for congenital heart disease, reported by Mitchell
and associates, supports the fact that infant heart
transplantation has now achieved a degree of success
comparable with transplantation in older children and
adults. Despite variations in immunosuppressive tech-
nique and surveillance monitoring, several institutions
have presented moderate-sized series of infant heart
transplantations with quite excellent results, such as
those reported here by Mitchell and associates, with
survivals of 70% or greater 2 years after transplanta-
tion. Thus it is clear that infant heart transplantation is
an effective palliative intervention for children who
have no other surgical or medical options. What re-
mains problematic, however, is the fact that human
donor availability will never meet the potential demand
if this therapy is used in patients with complex congen-
ital heart disease. Thus the success of transplantation
for infants with congenital heart disease has brought
about an entirely new set of potential problems. These
problems await the solution of suitable xenograft organ
availability. With the availability of a relatively unlim-
ited donor supply, the outstanding success of infant
heart transplantation as described by the Loma Linda
group, Mitchell’s group, and others may achieve its full
potential.
Thomas L. Spray, MD
Philadelphia, Pa.
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